The phase II oral HDACi tucidinostat mitigates the negative prognostic impact of CREBBP/EP300 mutations on DLBCL (ClinicalTrials.gov: NCT02753647) [125,126]. The gene discussed is EP300; the disease is diffuse large B-cell lymphoma.